Clinical trials
Leukemia, Myeloid clinical trials
Below are recruiting leukemia, myeloid clinical trials, each written for real people, not researchers. We’re tracking 575 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05503134RecruitingPhase 1/Phase 2
Donor immune cell treatment for relapsed or stubborn AML
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
Columbus, OhioAges 1–24 - NCT07670130Recruiting
Venetoclax TDM in Newly Diagnosed AML: Response and Outlook
This study looks at how the drug venetoclax works in people newly diagnosed with acute myeloid leukemia (AML). It helps doctors understand the right dose for better results.
SuzhouAges 16 years+ - NCT04168502RecruitingPhase 3
Gemtuzumab added to chemotherapy for certain adult AML
This Phase 3 trial tests whether adding gemtuzumab to standard chemotherapy helps people with newly diagnosed, favorable-intermediate AML reduce “MRD” (very small remaining leukemia cells). If MRD levels drop more, it may lower the chance of relapse.
AlessandriaAges 18–60 - NCT07617285RecruitingPhase 1
CAR-T cell therapy for relapsed or refractory acute myeloid leukemia
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
BeijingAges 18–70 - NCT07613385Recruiting
Personalized Treatment Plan for Relapsed or Resistant AML
This study tests a personalized approach to treating acute myeloid leukemia (AML) that has come back or stopped responding to prior treatments. Researchers will analyze your leukemia cells in the lab to find the best drug combination for your specific cancer, with the goal of improving treatment outcomes.
Duarte, CaliforniaAges 18 years+ - NCT07607418RecruitingPhase 2
Ivosidenib maintenance therapy for IDH1-mutated blood cancers
This trial tests whether taking ivosidenib as a maintenance drug (to keep the cancer in remission) works better than standard care for patients with IDH1-mutated AML or high-risk MDS who cannot undergo a bone marrow transplant. Ivosidenib is a targeted drug that blocks a specific mutation found in your cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07588360Recruiting
Stem cell transplant for acute myeloid leukemia or myelodysplastic syndrome
This trial tests a type of stem cell transplant (using cells from a partially matched donor and umbilical cord blood) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to help patients whose disease is high-risk, has returned after treatment, or hasn't responded well to chemotherapy.
Fuzhou, FujianAges 14–60 - NCT07583888RecruitingPhase 2/Phase 3
VABu Conditioning for Older Adults with Acute Myeloid Leukemia
This trial tests a chemotherapy regimen (VABu) combined with a stem-cell transplant for older adults (60+) with acute myeloid leukemia (a blood cancer) who previously responded well to Venetoclax-based treatment. The goal is to see if this approach improves outcomes after transplant.
Suzhou, JiangsuAges 60 years+ - NCT06724536Recruiting
Study of gut bacteria and TKIs in chronic myeloid leukemia
This trial looks at how gut bacteria affect the way chronic myeloid leukemia (CML) patients respond to tyrosine kinase inhibitor (TKI) medications. It may help doctors understand why some people have better outcomes than others.
TorinoAges 18 years+ - NCT07570407Recruiting
Blood Immune Cells After Bone Marrow Transplant for Leukemia
This study measures certain immune cells in your blood after a stem cell transplant for acute myeloid leukemia (AML). It aims to understand how well your immune system recovers and may help predict how you'll do after transplant.
Pilsen, CzechiaAges 18–70 - NCT07561892RecruitingPhase 4
Chemotherapy with or without silibinin for newly diagnosed blood cancer
This trial tests whether adding silibinin (a plant-based supplement) to standard chemotherapy drugs (daunorubicin or idarubicin) helps treat newly diagnosed acute myeloid leukemia (AML), a serious blood cancer. The goal is to see if this combination is more effective and safer than chemotherapy alone.
Fuzhou, FujianAges 18–65 - NCT05477589RecruitingPhase 3
Conditioning plan for kids with AML before stem cell transplant
This Phase 3 trial studies the best “conditioning” chemotherapy plan before an allogeneic stem cell transplant for children with AML. It may help improve outcomes by testing an approach for kids who are ready for transplant after relapse or specific high-risk features.
BrusselsAges Up to 18 years - NCT07548710RecruitingPhase 2
SA plus X for newly diagnosed AML
This trial tests a combination of two drugs, SA and X, for people who have just been diagnosed with acute myeloid leukemia (AML) and have not yet received treatment (except hydroxyurea to lower white blood cells). The goal is to see if the combination works better than standard care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07551037RecruitingPhase 1
Immune Therapy to Prevent AML Relapse After Chemotherapy
This trial tests a new type of maintenance therapy for acute myeloid leukemia (AML) patients who have already responded well to chemotherapy. The treatment uses your own immune cells to help prevent the cancer from coming back.
Fuzhou, FujianAges 18–70 - NCT07532824RecruitingPhase 1/Phase 2
Proton Radiation and Stem Cell Transplant for High-Risk Blood Cancers
This trial tests a new type of radiation therapy (proton-based) combined with a stem cell transplant from a donor to treat advanced forms of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to improve survival in patients with aggressive or hard-to-treat disease.
PragueAges 18–65 - NCT07511829Recruiting
Wearable Devices to Track Health in Blood Cancer Patients
This study uses wearable technology (like smartwatches) to monitor your health and quality of life while you receive treatment for blood cancers like myeloma or myelodysplastic syndromes. The goal is to help doctors better understand how blood transfusions and other supportive care affect how you feel day-to-day.
Oxford, OXFORDSHIREAges 18 years+ - NCT07507760RecruitingPhase 2
Oral decitabine plus ivosidenib for older AML patients
This trial tests a combination of two oral drugs (decitabine and ivosidenib) as a first treatment for older or frail adults with AML that has an IDH1 mutation. The goal is to see if this pill-only regimen is safe and effective without needing intensive chemotherapy.
AveiroAges 18 years+ - NCT07500441Recruiting
Gene test after stem cell transplant for AML
This trial uses a very sensitive blood test (digital PCR) to look for tiny amounts of leftover leukemia after a stem cell transplant, focusing on certain gene changes that are not the common fusion genes.
Beijing, Beijing MunicipalityAges Any age - NCT07500753Recruiting
Study of a conditioning regimen for older adults with hard-to-treat leukemia or MDS
This trial tests a chemotherapy combination (Clad-LABU) to prepare older patients for a stem cell transplant. It is for people aged 50 or older with relapsed or refractory AML or high-risk MDS.
Suzhou, JiangsuAges 50 years+ - NCT07486713RecruitingPhase 4
Olutasidenib drug interaction study for IDH1 mutation cancers
This trial tests how olutasidenib interacts with other drugs in people with cancers that have an IDH1 mutation, like certain leukemias or brain tumors. Participation may help determine the best way to take this treatment safely.
Orange, CaliforniaAges 18 years+ - NCT07478991RecruitingPhase 3
Azacitidine and venetoclax with or without quizartinib for older or unfit AML patients
This trial tests if adding quizartinib to the standard combination of azacitidine and venetoclax improves outcomes for older adults or those with health conditions who cannot have intensive chemotherapy for acute myeloid leukemia (AML). It may help patients with certain genetic changes in the FLT3 or NPM1 genes.
Santiago de Compostela, A CoruñaAges 18 years+ - NCT05601726RecruitingPhase 1/Phase 2
Study of a new drug for hard-to-treat AML or high-risk MDS
This early study tests a new medicine (ABD-3001) to see if it’s safe and tolerable, how the body handles it, and whether it shows early signs of helping people with relapsed or hard-to-treat AML or high-risk MDS. It may be an option if standard treatments have already failed and you can’t receive a stem cell transplant.
Marseille, FranceAges 18 years+ - NCT07463651RecruitingPhase 3
Gilteritini vs Sorafenib after transplant for FLT3-ITD AML
This trial tests two maintenance drugs (gilteritini and sorafenib) for people with FLT3-ITD positive AML after a stem cell transplant. It compares which drug better prevents relapse using a sensitive test for minimal residual disease (MRD).
Suzhou, JiangsuAges 14–70 - NCT07451912RecruitingPhase 1/Phase 2
Venetoclax Combo for CEBPA-Mutated AML in Unfit Patients
This trial tests a combination of three drugs (venetoclax, a hypomethylating agent, and low-dose cytarabine) for people with newly diagnosed AML that has a CEBPA gene mutation and who are not strong enough for standard intensive chemotherapy. The goal is to see if this gentler approach works well.
Suzhou, JiangsuAges 18 years+
Hear when a new Leukemia, Myeloid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia, myeloid?
- Yes. Clin2 currently lists 575 recruiting leukemia, myeloid studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia, myeloid trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia, myeloid trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.